Aspire Biopharma shares surge 15.09% premarket after partnering with Microsize to develop sublingual aspirin for emergency heart attack treatment, advancing NDA plans.

Aspire Biopharma (ASBP) surged 15.09% in premarket trading following its announcement of a strategic partnership with Microsize, a leading contract development and manufacturing organization (CDMO) specializing in particle size engineering. The collaboration aims to advance Aspire’s lead drug candidate—a 162 mg sublingual aspirin powder for emergency heart attack treatment—toward a clinical trial and a Section 505(b)(2) New Drug Application (NDA) submission by late 2026. Microsize’s expertise in cGMP micronization and solubility enhancement is critical for optimizing the drug’s formulation and commercial readiness. The partnership aligns with Aspire’s broader strategy to improve existing therapeutics through rapid, targeted delivery technology. CEO Kraig Higginson emphasized the agreement’s role in accelerating regulatory progress and reinforcing U.S.-based innovation. The move underscores investor optimism about the company’s path to product development and potential market differentiation in acute care.